Wiki

Prednisolone

Sources

Prednisolone

Clinical Summary

Prednisolone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties.

Documented on handwritten prescription as "Predniod" (likely misspelling of prednisolone).

Newly documented from handwritten prescription dated 2026-05-04. Dosing: 1-0-1 for 15 days (twice daily for 15 days). Dose not specified on Rx (likely 5–10 mg).

**NOT BEING TAKEN — Confirmed 2026-05-06**

Clinic note dated 2026-05-06 confirms patient is not taking prednisolone (Predniod). Status changed active → discontinued. Same non-adherence pattern as nifedipine (2026-05-06a) and atorvastatin (2026-05-06b). It is unknown whether the patient never started the course, or started and stopped. The 15-day course was prescribed on 2026-05-04; if never started, no steroid effect has occurred. The hyperglycemia and infection risks flagged below are therefore NOT currently active.

Dosing History

Date Dose Frequency Route Duration Context
2026-05-04 Unknown (likely 5–10 mg) Twice daily (1-0-1) Oral 15 days (short course) Documented from handwritten Rx ("Predniod")
**Major Documentation Gap**

This medication was NOT previously documented in any ingested raw source. Indication is unknown. This is a short 15-day course, suggesting treatment of an acute inflammatory or allergic condition, not chronic therapy.

[!note] Short Course — Not Chronic
Prednisolone is prescribed for 15 days only (1-0-1 × 15 days). This is a short course, not chronic therapy. After 15 days, it should be discontinued (possibly with taper if dose is high).

Indication (UNKNOWN)

Indication is not documented. Possible reasons for short-course prednisolone:

Possible Indications

  1. Acute inflammatory condition (arthritis flare, bursitis, tendonitis)
  2. Allergic reaction / dermatologic condition (rash, contact dermatitis, urticaria)
  3. Respiratory condition (asthma exacerbation, COPD flare, pneumonitis) — not documented
  4. AML-related (cytokine release syndrome? Transfusion reaction? Tumor lysis syndrome?) — unlikely but possible
  5. Drug reaction (to chemotherapy or other medication)
  6. Autoimmune flare (Ishamma has positive ANA 2.2, but no documented autoimmune disease)
  7. Acute gout (though no hyperuricemia documented)

No symptoms, physical findings, or clinical context documented in available sources.

Pharmacology

  • Drug class: Corticosteroid (glucocorticoid)
  • Mechanism: Binds to glucocorticoid receptor → alters gene transcription → suppresses inflammatory mediators (cytokines, prostaglandins, leukotrienes) and immune response
  • Equivalent potency: 5 mg prednisolone ≈ 4 mg methylprednisolone ≈ 0.75 mg dexamethasone ≈ 20 mg hydrocortisone
  • Half-life: ~3–4 hours (biological activity longer, ~12–36 hours)

Monitoring — CRITICAL in Diabetes + AML

Parameter Frequency Rationale Ishamma Status
Blood glucose Daily (home monitoring) Hyperglycemia — steroids worsen diabetes control Fructosamine 310 (HIGH, Apr 2026) — already poor control
Blood pressure Daily Hypertension, fluid retention Not documented (on losartan + nifedipine)
Weight / fluid status Daily Fluid retention, edema Not documented
Infection signs Daily Immunosuppression increases infection risk Neutropenic during AML treatment (ANC 2360 May 4, recovered)
Mood / behavior Daily Steroid-induced psychiatric effects (agitation, insomnia, psychosis) Not documented
GI symptoms Daily Gastritis, peptic ulcer risk Not documented

[!danger] Hyperglycemia Risk in Diabetes
Prednisolone causes hyperglycemia and insulin resistance. Ishamma has Diabetes Mellitus with already poor control (fructosamine 310, HIGH). Steroids will worsen this.

Management:
- Increase insulin doses (both basal Insulin Degludec and Insulin Glargine)
- Increase home glucose monitoring frequency
- Consider temporary increase in oral diabetes meds (metformin, linagliptin)
- Monitor fructosamine or HbA1c after steroid course

**Infection Risk in Neutropenic Patient**

Prednisolone is immunosuppressive. Ishamma is on Azacitidine and Venetoclax (myelosuppressive chemotherapy). During neutropenic nadirs, steroids further increase infection risk.

Current status: ANC 2360 cells/cumm (May 4) — recovered. But steroid course may coincide with next chemotherapy nadir.

[!info] No Taper Mentioned
Handwritten Rx states "1-0-1 × 15 days" with no mention of taper. For a 15-day course:
- If dose is LOW (≤10 mg/day): usually no taper needed, can stop abruptly
- If dose is MODERATE-HIGH (>10 mg/day): taper recommended to prevent adrenal insufficiency

Dose is not specified on Rx, so taper necessity is unclear.

Drug Interactions

  • Insulin / oral diabetes medications: Steroids antagonize insulin action → increased glucose, requiring higher insulin doses
  • NSAIDs: Increased GI bleeding/ulcer risk (both are gastric irritants)
  • Vaccines (live): Avoid live vaccines during steroid therapy (immunosuppression)
  • CYP3A4 inducers (rifampin): Reduce prednisolone levels
  • CYP3A4 inhibitors (posaconazole): May modestly increase prednisolone levels (minor effect)

Adverse Effects (Short-Term Use)

Effect Risk in 15-Day Course Ishamma-Specific Risk
Hyperglycemia High Very high (diabetes + already poor control)
Hypertension / fluid retention Moderate Moderate (on antihypertensives)
Infection risk Moderate High (AML, chemotherapy, neutropenia risk)
Insomnia / agitation Moderate Moderate (elderly)
GI upset / gastritis Low-Moderate Moderate (on NSAIDs if any)
Mood changes / psychosis Low (short course) Moderate (elderly, age 81)
Adrenal suppression Low (15 days usually insufficient) Low
Osteoporosis Very low (requires chronic use) N/A
Cataracts / glaucoma Very low (requires chronic use) N/A

Related

  • Diabetes Mellitus — Steroids worsen glucose control; increase insulin requirements
  • Insulin Degludec — May need dose increase during steroid course
  • Insulin Glargine — May need dose increase during steroid course
  • Fructosamine — Already HIGH (310); will worsen with steroids
  • Aml — Infection risk compounded by chemotherapy-induced neutropenia
  • Positive Ana — Possible autoimmune indication (undocumented)

Medication page created during ingest of 2026-05-04 handwritten prescription. Indication unknown. Short 15-day course. Dose not specified. Patient confirmed NOT taking this medication (2026-05-06 clinic note). Status: discontinued.

Care Insights · wiki page · prednisolone